scholarly journals PCN31 Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment for Patients with HER2-Positive EARLY Breast Cancer: Update Results after National Drug Reimbursement LIST Adjustment in China

2020 ◽  
Vol 22 ◽  
pp. S10
Author(s):  
X. Guan ◽  
H.C. Li ◽  
Q.J. Chen ◽  
C.F. Hao ◽  
J.J. Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Early Breast Cancer ◽  
Adjuvant Treatment ◽  
Cost Effectiveness Analysis ◽  
Her2 Positive ◽  
Drug Reimbursement ◽  
Effectiveness Analysis ◽  
National Drug ◽  
Reimbursement List

Therapie des Mammakarzinoms – Ist die zusätzliche Gabe von Pertuzumab kosteneffektiv?

2020 ◽  
Vol 25 (01) ◽  
pp. 6-6
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cost Effectiveness ◽  
Adjuvant Treatment ◽  
The United States ◽  
Cost Effectiveness Analysis ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Effectiveness Analysis ◽  
Positive Breast Cancer

Garrison L et al. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value Health 2019: 22(4): 408–415 Bis zu 20 % der Frauen, die von Brustkrebs betroffenen sind, zeigen eine erhöhte Konzentration des Humanen Epidermalen Wachstumsfaktor-Rezeptors 2 (HER2). HER2-positiver Brustkrebs führt im Verlauf häufig zu Rezidiven und bedarf einer zielgerichteten Therapie. Garrison et al. untersuchten in diesem Zusammenhang die Kosten-Effektivität einer zusätzlichen Gabe von Pertuzumab.

Sign in / Sign up

Export Citation Format

Share Document